Heruntergeprügelter EM-Pharmawert: Hikma Pharmaceuticals Plc
eröffnet am 25.08.17 21:37:13 von
neuester Beitrag 05.02.23 14:08:43 von
neuester Beitrag 05.02.23 14:08:43 von
Beiträge: 14
ID: 1.260.247
ID: 1.260.247
Aufrufe heute: 0
Gesamt: 757
Gesamt: 757
Aktive User: 0
ISIN: GB00B0LCW083 · WKN: A0HG69 · Symbol: H5P
23,200
EUR
+1,75 %
+0,400 EUR
Letzter Kurs 03.05.24 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 1,2100 | +21,00 | |
| 43,60 | +20,01 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,050 | -12,55 | |
| 4,0300 | -12,96 | |
| 6,2600 | -14,25 | |
| 3,8500 | -14,45 | |
| 1,4500 | -20,98 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 66.573.563 von faultcode am 23.01.21 11:54:57https://www.marketwatch.com/story/hikma-profit-falls-but-bea…
Hikma Pharmaceuticals PLC on Thursday reported a 11% fall in 2020 net profit but still beat market forecasts.
Net profit for the year ended Dec. 31 was $431 million compared with $486 million in 2019 and a consensus of $390.9 million, taken from FactSet and based on four analysts' forecasts.
Revenue for the year was $2.34 billion compared with $2.21 billion. Within this generics revenue was $744 million compared with the company's expectations of between $720 million and $740 million. Core revenue from its injectables business was $977 million, compared with expectations of $950 million to $980 million.
For the year ahead the company expects to report injectables revenue growth in the mid-single digits, with core operating margin in the range of 37% to 38%. Generics revenue is expected to be in the range of $770 million to $810 million, with a core operating margin of around 20%.
The board declared a total dividend for the year of 50 cents a share, up from 44 cents in 2019.
...
Hikma Pharmaceuticals PLC on Thursday reported a 11% fall in 2020 net profit but still beat market forecasts.
Net profit for the year ended Dec. 31 was $431 million compared with $486 million in 2019 and a consensus of $390.9 million, taken from FactSet and based on four analysts' forecasts.
Revenue for the year was $2.34 billion compared with $2.21 billion. Within this generics revenue was $744 million compared with the company's expectations of between $720 million and $740 million. Core revenue from its injectables business was $977 million, compared with expectations of $950 million to $980 million.
For the year ahead the company expects to report injectables revenue growth in the mid-single digits, with core operating margin in the range of 37% to 38%. Generics revenue is expected to be in the range of $770 million to $810 million, with a core operating margin of around 20%.
The board declared a total dividend for the year of 50 cents a share, up from 44 cents in 2019.
...
Antwort auf Beitrag Nr.: 66.573.563 von faultcode am 23.01.21 11:54:57Ich habe mal ein paar zu 27,60 € ins Depot gelegt...
Antwort auf Beitrag Nr.: 62.608.453 von faultcode am 06.02.20 21:51:15
Antwort auf Beitrag Nr.: 61.153.193 von faultcode am 01.08.19 16:15:14..und bleibt auf der Watch:
https://www.marketscreener.com/HIKMA-PHARMACEUTICALS-PLC-959…
https://www.marketscreener.com/HIKMA-PHARMACEUTICALS-PLC-959…
Trading Spotlight
Antwort auf Beitrag Nr.: 56.844.064 von faultcode am 26.01.18 19:59:51ja, das war der Boden -- leider ohne mich 
Antwort auf Beitrag Nr.: 56.121.626 von faultcode am 07.11.17 15:23:15
Hikma Pharmaceuticals PLC (HIK.LN) lowered its guidance for its generics unit for the third time on Thursday, but said that it still expects group revenue to be around $2.0 billion in constant currency.
The multinational pharmaceutical expects generics unit revenue to be around $600 million compared with its previous guidance of $620 million given in August. It blamed continued challenging market conditions for the lower guidance, adding that it sees the core operating margin for the unit in the low single-digits.
...
"We are also identifying further cost savings for this business, which will include the consolidation of our oral manufacturing operations in the U.S.," it said.
=> TEVA -1.45% sehe ich gerade...
..immer weiter --> heute -7%
https://www.marketwatch.com/story/hikma-cuts-guidance-on-gen…Hikma Pharmaceuticals PLC (HIK.LN) lowered its guidance for its generics unit for the third time on Thursday, but said that it still expects group revenue to be around $2.0 billion in constant currency.
The multinational pharmaceutical expects generics unit revenue to be around $600 million compared with its previous guidance of $620 million given in August. It blamed continued challenging market conditions for the lower guidance, adding that it sees the core operating margin for the unit in the low single-digits.
...
"We are also identifying further cost savings for this business, which will include the consolidation of our oral manufacturing operations in the U.S.," it said.
=> TEVA -1.45% sehe ich gerade...
Antwort auf Beitrag Nr.: 55.601.590 von faultcode am 25.08.17 23:48:50
https://www.wallstreet-online.de/diskussion/948841-1781-1790…
=> dieser Abwärtstrend ist säkular, und damit sehr ernst zu nehmen. Grosse Adressen verlassen íhre Generika-Positionen. Ohne solche aber kein Aufwärtstrend.
Auch in den letzten 3 Monaten hat man mit Teva und Hikma Pharmaceuticals als Longie Geld verloren (als Positions-Investor oder Anleger).
=> ein möglicher Kauf hier muss daher weiter warten - Geduld ist hier die allerbeste Tugend.
(dass Teva erneute Mylan verklagt, zeigt nur wie wenig Spass im globalen Generika-Markt z.Z. drinnen ist.)
Rünterprügeln geht weiter...
...egal wieviel (indirekter) Optimismus im TEVA-ADR-Forum verbreitet wird:https://www.wallstreet-online.de/diskussion/948841-1781-1790…
=> dieser Abwärtstrend ist säkular, und damit sehr ernst zu nehmen. Grosse Adressen verlassen íhre Generika-Positionen. Ohne solche aber kein Aufwärtstrend.
Auch in den letzten 3 Monaten hat man mit Teva und Hikma Pharmaceuticals als Longie Geld verloren (als Positions-Investor oder Anleger).
=> ein möglicher Kauf hier muss daher weiter warten - Geduld ist hier die allerbeste Tugend.
(dass Teva erneute Mylan verklagt, zeigt nur wie wenig Spass im globalen Generika-Markt z.Z. drinnen ist.)
Durchsuchen
Heruntergeprügelter EM-Pharmawert: Hikma Pharmaceuticals Plc
